AVAL, Quebec, Jan. 25, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today released a memo sent to Valeant employees from J. Michael Pearson, who is currently out on medical leave.
The full text of the memo to employees is as follows:
GrizzlyRock Value Partners was up 34.54% net for 2021. The fund marked 10 years since its inception with a 198% net return, resulting in an annual return of 11.5%. GrizzlyRock enjoyed 14.8% long alpha against the S&P 500 and 26.9% against the Russell 2000. Q4 2021 hedge fund letters, conferences and more The fund's short Read More
I want to thank everyone for the outpouring of support and well wishes you have expressed over the past few weeks. As you know, I unexpectedly entered the hospital in late December to receive treatment for severe pneumonia and some unexpected complications resulted in a longer hospital stay than anticipated. I’m glad to say that I’m on the road to recovery and although the timing of my return remains uncertain, I look forward to being back at work when able.
I would like to thank all of you for the hard work and diligence you have demonstrated during my absence by continuing to deliver important medicines and products to the doctors and patients who need them. I specifically want to thank Howard for stepping in as Interim CEO and to all the members of the management team for the leadership that they have shown. While the past few months have been difficult, I am convinced we will emerge stronger than ever and our future remains bright.
With best regards,
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.